ATE418562T1 - Ctl epitope des epstein-barr virus - Google Patents

Ctl epitope des epstein-barr virus

Info

Publication number
ATE418562T1
ATE418562T1 AT98931834T AT98931834T ATE418562T1 AT E418562 T1 ATE418562 T1 AT E418562T1 AT 98931834 T AT98931834 T AT 98931834T AT 98931834 T AT98931834 T AT 98931834T AT E418562 T1 ATE418562 T1 AT E418562T1
Authority
AT
Austria
Prior art keywords
seq
ebv
epstein
barr virus
ctl epitopes
Prior art date
Application number
AT98931834T
Other languages
English (en)
Inventor
Scott Burrows
Rajiv Khanna
Original Assignee
Queensland Inst Med Res
Commw Scient Ind Res Org
Univ Melbourne
Inst Medical W & E Hall
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Inst Med Res, Commw Scient Ind Res Org, Univ Melbourne, Inst Medical W & E Hall, Csl Ltd filed Critical Queensland Inst Med Res
Application granted granted Critical
Publication of ATE418562T1 publication Critical patent/ATE418562T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT98931834T 1997-07-10 1998-07-10 Ctl epitope des epstein-barr virus ATE418562T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7841A AUPO784197A0 (en) 1997-07-10 1997-07-10 Treatment of nasopharyngeal carcinoma

Publications (1)

Publication Number Publication Date
ATE418562T1 true ATE418562T1 (de) 2009-01-15

Family

ID=3802132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931834T ATE418562T1 (de) 1997-07-10 1998-07-10 Ctl epitope des epstein-barr virus

Country Status (11)

Country Link
US (2) US6723695B1 (de)
EP (1) EP1003773B1 (de)
JP (1) JP2001509514A (de)
CN (1) CN100526331C (de)
AT (1) ATE418562T1 (de)
AU (1) AUPO784197A0 (de)
CA (1) CA2294732A1 (de)
DE (1) DE69840383D1 (de)
NZ (1) NZ501944A (de)
WO (1) WO1999002550A1 (de)
ZA (1) ZA986084B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2392456A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
WO2004067032A2 (en) 2003-01-24 2004-08-12 University Of Massachusetts Medical Center Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
US8067535B2 (en) 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
FR2850384A1 (fr) * 2003-01-28 2004-07-30 Centre Nat Rech Scient Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
US8451808B2 (en) 2006-02-18 2013-05-28 Intel Corporation Techniques for 40 megahertz (MHz) channel switching
EP1826264A1 (de) * 2006-02-24 2007-08-29 Deutsches Primatenzentrum GmbH Primatmodell für Orthopoxvirus-Infektionen
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
CN102812043A (zh) * 2009-11-19 2012-12-05 新加坡国立大学 用于制备t细胞受体样单克隆抗体的方法及其用途
US20140086888A1 (en) * 2010-09-01 2014-03-27 Helen E. Heslop Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (de) 2012-02-09 2019-07-17 Baylor College Of Medicine Peptidmischungen zur erzeugung multiviraler ctl mit breiter spezifität
US10040827B2 (en) 2012-03-19 2018-08-07 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing T-cell epitopes
JP2015533366A (ja) 2012-10-19 2015-11-24 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 改良されたヒトヘルペスウイルス免疫療法
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
US10016494B2 (en) 2014-02-07 2018-07-10 Valorisation-Hsj, Limited Partnership Antigenic epitopes from EBV gp350/220 and uses thereof
EP3131575B1 (de) 2014-04-15 2024-05-08 Griffith University Streptokokken-impfstoffgruppe
EP3215165B1 (de) 2014-11-05 2020-12-23 Memorial Sloan Kettering Cancer Center Verfahren zur auswahl einer t-zell-linie und spender davon zur adoptiven zelltherapie
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
US10568908B2 (en) 2015-05-12 2020-02-25 Memorial Sloan Kettering Cancer Center Methods of treating Epstein-Barr virus-associated lymphoproliferative disorders by T cell therapy
KR101794304B1 (ko) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ebv 항원 특이 t―세포 수용체 및 이의 용도
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
PT3384052T (pt) * 2015-12-04 2020-06-08 Singapore Health Serv Pte Ltd Correlatos clínicos de eficácia de imunoterapia
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN109475578A (zh) * 2016-05-25 2019-03-15 昆士兰医学研究所理事会 使用同种异体t细胞治疗自身免疫疾病的方法
DK3507300T3 (da) 2016-09-02 2023-03-27 Univ James Cook Sårhelende peptid
CA3037002A1 (en) 2016-09-23 2018-03-29 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory t cells
CN106397574A (zh) * 2016-10-21 2017-02-15 上海交通大学医学院附属新华医院 抗原表位肽及其应用
KR102703633B1 (ko) 2016-11-09 2024-09-05 그리피스 유니버시티 서브틸라제 세포독소 b 서브유닛 돌연변이체
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
CA3064375A1 (en) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
EP3700553A1 (de) 2017-10-23 2020-09-02 Atara Biotherapeutics, Inc. Verfahren für das management von tumorschüben bei der adoptiven immuntherapie
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
MX2022006299A (es) 2019-11-25 2023-01-19 Univ Griffith Proteína inmunogénica contra una infección gonocócica.
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰(北京)生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
KR20230107553A (ko) * 2020-10-07 2023-07-17 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 헤르페스바이러스 폴리에피토프 백신
EP4232076A1 (de) 2020-10-20 2023-08-30 The Chancellor, Masters and Scholars of The University of Oxford Verfahren und zusammensetzungen zur behandlung von epstein-barr-virus-assoziiertem krebs
CN115786509A (zh) * 2022-10-21 2023-03-14 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种鼻咽癌患病风险预测试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
WO1993019092A1 (fr) 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
AU1942595A (en) * 1994-03-16 1995-10-03 Csl Limited Cytotoxic t-cell epitopes
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
MY114769A (en) * 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
WO1996003144A1 (en) * 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
AU3072395A (en) * 1994-07-27 1996-02-22 Csl Limited Polyepitope vaccines
GB9501300D0 (en) * 1995-01-24 1995-03-15 Boughton Brian J Peptides which inhibit viruses
AUPO007396A0 (en) * 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AU712364B2 (en) * 1996-05-24 1999-11-04 Council Of The Queensland Institute Of Medical Research, The EBV CTL epitopes

Also Published As

Publication number Publication date
JP2001509514A (ja) 2001-07-24
CN1269804A (zh) 2000-10-11
AUPO784197A0 (en) 1997-08-07
EP1003773B1 (de) 2008-12-24
EP1003773A4 (de) 2002-08-07
CN100526331C (zh) 2009-08-12
US6723695B1 (en) 2004-04-20
WO1999002550A8 (en) 2000-06-15
ZA986084B (en) 1999-01-26
WO1999002550A1 (en) 1999-01-21
NZ501944A (en) 2001-11-30
CA2294732A1 (en) 1999-01-21
US20030152582A1 (en) 2003-08-14
DE69840383D1 (de) 2009-02-05
EP1003773A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
DE69840383D1 (de) Ctl epitope des epstein-barr virus
NZ335612A (en) A composition containing cytotoxic specificT-cell epitopes being either Rev and/or Tat proteins from HIV virus for prevention and treatment of human immunodeficiency virus (HIV) infection
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
BR9814487A (pt) "vacina"
IL189629A0 (en) Compositions containing human ctla-4 antibodies
CY2570B1 (en) Compounds for immunotherapy and diagnosis of tuberculosis
EP0726758A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
GB2301591A (en) Cytotoxic T-cell epitopes
EP0687182A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
CA2192512A1 (en) Nm03 antibody materials and methods
GB2332907B (en) EBV CTL Epitopes
EP0770624A3 (de) Peptid das eine Immunantwort gegen menschlichen Magenkrebs induziert und Arzneimittel die es enthält zur Vorbeugung oder Behandlung von Magenkrebs
NO920331D0 (no) Biologisk preparat samt bruk derav
GR3019859T3 (en) Synthetic vaccine for the specific induction of cytotoxic T-lymphocytes
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
OA09037A (en) Prevention and treatement of retroviral disease.
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
SE9600436D0 (sv) Vaccine against hantavirus
AP2001002354A0 (en) Use of antibodies recognizing the interleukin-2 receptor in the prevention and /or treatment of infections by the AIDS viruses.
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
WO2000024876A3 (en) Spumavirus isolated from humans

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties